Company news
Biostax Corp. (OTC:BTAX) news
Biostax Corp. news releases on 6ix. Latest, Feb 21, 2025: Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration
Press releases & updates
Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration
February 21, 2025
Immune Therapeutics, Inc. Provides Shareholder Update on 14A
May 15, 2019
Immune Therapeutics welcomes Kevin Phelps to Board of Directors
January 9, 2019
Research on Lodonal (“LDN”) for HIV-related GI complications, and Inflammation featured in A&U Magazine
December 13, 2018
Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors
September 6, 2018
Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry
September 5, 2018
Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Board
August 23, 2018
Immune Therapeutics Adds Former United States Assistant Surgeon General Dr. Roscoe Moore to Board of Directors
August 7, 2018
Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies
July 25, 2018
Research on Lodonal for HIV related GI complications featured in Plus Magazine
July 19, 2018
(CORRECTION) Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States
June 5, 2018
Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States
June 5, 2018
Immune Therapeutics, Inc. Files New Drug Application for Lodonol™ in Kenya to Target HIV Epidemic
April 26, 2018
Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease
March 26, 2018
Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria
February 20, 2018
Immune Therapeutics, Inc. Shareholder Update Letter
November 30, 2017
Immune Therapeutics, Inc. Announces Exclusive Agreement for Sale of Lodonal in Kenya Valued at Over $31 Million
September 6, 2017
Immune Therapeutics, Inc. Announces Exclusive Agreement For Sale Of Lodonal In Kenya Valued At Over $31 Million
September 6, 2017
Immune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc.
August 23, 2017
Immune Therapeutics to Present at the 7th Annual LD Micro Invitational
June 4, 2017
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 201
May 31, 2017
CORRECTING and REPLACING: Immune Therapeutics, Inc.
May 22, 2017
Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria
May 22, 2017
Immune Therapeutics, Inc. Files Lodonal New Drug Application in Kenya
April 25, 2017
Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya
April 17, 2017
Immune Therapeutics, Inc. Strengthens Balance Sheet With Debt Settlement
April 12, 2017
Immune Therapeutics, Inc. Announces Expansion of Patent Portfolio
March 30, 2017
Immune Therapeutics, Inc. Further Strengthens Balance Sheet as it Prepares for Commercialization
March 15, 2017
IMMUNE THERAPEUTICS STRENGTHENS BALANCE SHEET; Reiterates Outlook for Positive Cash Flow by Mid Year
February 9, 2017
Immune Therapeutics Clears Critical Certification Milestone
February 2, 2017
UPDATE -- Immune Therapeutics Issues Special Letter to Shareholders
January 30, 2017
Immune Therapeutics Issues Special Letter to Shareholders
January 30, 2017
Immune Therapeutics Announces Special Investor Conference Call to Discuss 2017 Outlook
January 27, 2017
Immune Therapeutics Retains Investor Relations Partners to Support Company’s Strategic IR Program as it Prepares for Commercialziation
January 26, 2017
Immune Therapeutics Statement on the Death of Christopher Pearce, Founder and Chief Operating Officer
December 12, 2016
Immune Therapeutics Redeems $656,250 Convertible Note; Company Actively Working to Strengthen Balance Sheet by Year End
November 15, 2016
Immune Therapeutics Announces Filing Acceptance of New Drug Applications for Lodonal™ for the Treatment of Patients with Human Immuno-Deficiency, Cancer and as an Immune Booster
October 26, 2016
Immune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board
September 22, 2016
Immune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer
August 23, 2016
Immune Therapeutics, Inc. to Hold an Informational Shareholder Meeting on Wednesday, August 17, 2016 at 10 A.M. EDT
July 26, 2016
Immune Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
June 15, 2016
Lodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World's Leading Health Forums
May 19, 2016
Lodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World’s Leading Health Forums
May 18, 2016
Immune Therapeutics Receives NAFDAC Approval for Lodonal(TM) in Nigeria: Approval Follows Successful Recent Bridging Study
April 27, 2016
Immune Therapeutics Signs Binding Letter of Intent to Acquire Chinese CAR-T Technology and Clinical Data
April 21, 2016
Immune Therapeutics, Inc. Provides Drug Development Program Status Update on Methionine-Enkelphine ("MENK") in China
April 11, 2016
Immune Therapeutics, Inc., Appoints Two New Board Members
March 3, 2016
Fidson Healthcare Plc and GB Pharma Holdings position pharmaceutical outreach into Nigeria and Beyond!
January 27, 2016
OTC Markets Group Welcomes Newly Verified OTCQB Companies – June 15
June 15, 2015
Immune Therapeutics Inc, Announces the official publication announcement of the NAFDAC approved 90-Day Bridging Trial of Lodonal™ with HIV/AIDS Patients.
May 4, 2015